


エーザイ株式会社

Safe Harbor Statement




Recap of FY2015 Performance






	FY2014		FY2015		
	Results	%	Results	%	YoY
Revenue	548.5	100.0	547.9	100.0	100
Cost of sales	193.6	35.3	194.5	35.5	100
Gross profit	354.9	64.7	353.5	64.5	100
R&D expenses	131.9	24.1	122.3	22.3	93
SG&A expenses	194.5	35.5	192.8	35.2	99
Other income & expenses	(0.1)	(0.0)	13.6	2.5	
Operating profit	28.3	5.2	51.9	9.5	



<Major factors for decrease>
¥ Q2 FY2014
Divesture of marketing rights of Zonegran in U.S.
E3710 license agreement with Zeria Pharmaceutical Co., Ltd.
¥ Q4 FY2014
Epizyme, Inc. milestone payment receipt associated with
change of the scope of collaboration



+9.6

FY2016: Initial year of EWAY 2025



Strategic
Intent 1

Strategic
Intent 2

Strategic
Intent 3

Investigational Lemborexant*¹

Orexin receptor antagonist

Maximize potential value as a new insomnia treatment



Sleep disorder in the elderly

GABA²-gated insomnia treatment, one of the major insomnia treatments today, may impact sleep quality, memory impairment, nocturnal awakening, nighttime imbalance and falling, and others impacting the elderly^{*3}

Sleep disorder associated with AD

- J Sleep-wake fragmentation
- J Reduction in nocturnal sleep
- J Nocturnal wandering
- J Daytime sleepiness

Sleep disorder is one of the clinical concerns in patients with AD as it may accelerate cognitive function decline and burden caregivers

Development status of lemborexant seeking to fulfill patients' needs

Plan to initiate Phase III study for insomnia in Q1 FY2016

Approx. 40% enrollment will be elderly patients (age 65 years or over) aiming for differentiation from conventional insomnia treatments

Development under preparation for **sleep-wake fragmentation in dementia** as a potential new indication

Plan to initiate Phase II study in FY2016

*1: Investigational. Co-development with Purdue Pharma

*2: Gamma-aminobutyric acid

*3: Sleep proceeds in cycles of REM and NREM. GABA-gated insomnia treatments has an inhibitory effect on REM.

Investigational E2027 PDE9^{*1} inhibitor

Aiming for improvement of core symptoms^{*2}
and BPSD^{*3} in patients with dementia



cyclic GMP^{*4}

BACE inhibitor E2609*1: Phase II study


Anti A-beta antibody BAN2401*1: Phase II Study

Project targeting Tau: Preclinical

Orexin receptor antagonist Lemborexant*2
Sleep-wake fragmentation in dementia
Initiation of Phase II study planned in FY2016

Dementia solutions business in Japan

∅ Provide dementia solution which contributes toward realization of symbiotic society for dementia through collaboration with community healthcare supporters such as doctors, pharmacists, nurses, care workers, care givers/families and others, at 56 dementia coordination partners in Japan



LENVIMA



Value maximization through potential new indication for renal cell carcinoma and submission for hepatocellular carcinoma

Renal cell carcinoma 2nd line in combination with everolimus
U.S.: PDUFA^{*1} action date anticipated on May 16, 2016

EU: Approval anticipated in 1H FY2016

Aim to provide new treatment option for patients with renal cell carcinoma, which remained significant unmet medical needs for low 5-year survival rates

Hepatocellular carcinoma 1st line

Phase III study ongoing and global submission anticipated in FY2016

Combination regimens with immune checkpoint inhibitor^{*2}

Lung cancer, melanoma, head and neck cancer, bladder cancer, renal cell carcinoma and endometrial cancer

Phase II part of Phase Ib/II study ongoing

- All 6 types of tumors proceeded to Phase II part with fixed dose from confirmed combinability and clinical activities
- Plan to pres1 022: Anti

Biliary tract cancer 2nd line


Phase II study ongoing in Japan


Endometrial cancer

Phase IIb study under preparation


The graphic features two stacked cylinders. The top cylinder is light blue and is empty. The bottom cylinder is light purple and contains a red and black horizontal bar. The text "Americas Region Management" is written in white on the black portion of this bar.

Americas Region Management





Financial Integrity to Ensure Continued Strategic Investments and Stable Dividend



Reference Data




Performance of Japan Pharmaceutical Business



	FY2014		FY2015		
	Results	%	Results	%	YoY
Revenue	278.4	100.0	266.8	100.0	96
Prescription medicines	245.5	88.2	233.9	87.7	95
Aricept	46.9	16.9	40.5	15.2	86
Humira	29.9	10.7	32.6	12.2	109
Pariet* ¹	37.1	13.3	30.4	11.4	82
Lyrica* ²	21.5	7.7	24.7	9.3	115
Methycobal	22.4	8.0	20.8	7.8	93
Warfarin	8.6	3.1	7.6	2.9	88
Halaven	6.1	2.2	6.8	2.5	112
Actonel	6.7	2.4	6.4	2.4	96
Lunesta	4.5	1.6	6.0	2.2	132
Selbex	4.7	1.7	3.8	1.4	81
Lenvima			1.5	0.6	
Generics	26.9	9.7	28.5	10.7	106
Diagnostics	6.0	2.1	4.4	1.6	74
Segment profit* ³	122.4	44.0	111.6		







(Billion yen, %)